{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:03:56Z","timestamp":1786122236841,"version":"build-2736575974"},"reference-count":35,"publisher":"Informa UK Limited","issue":"17","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"GlaxoSimthKline","award":["221309"],"award-info":[{"award-number":["221309"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.1080\/14796694.2026.2692028","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:24:48Z","timestamp":1782393888000},"page":"2089-2099","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment landscape and disease burden of myelofibrosis in Taiwan, South Korea, Japan, and Canada"],"prefix":"10.1080","volume":"22","author":[{"given":"Kingo","family":"Kanda","sequence":"first","affiliation":[{"name":"GSK","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1853-974X","authenticated-orcid":false,"given":"Yusuke","family":"Yasutomi","sequence":"additional","affiliation":[{"name":"GSK","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wear","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-2392","authenticated-orcid":false,"given":"Adenike","family":"Adelakun Omomia","sequence":"additional","affiliation":[{"name":"GSK","place":["Mississauga, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Chang","sequence":"additional","affiliation":[{"name":"GSK","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2872-8455","authenticated-orcid":false,"given":"In-Kyeong","family":"Chun","sequence":"additional","affiliation":[{"name":"GSK","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"GSK","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S51800"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_3_8_5_1","unstructured":"Orphanet. Primary myelofibrosis. [cited 2024 Aug]. Available from: https:\/\/www.orpha.net\/en\/disease\/detail\/824"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062188"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00744-9"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.543"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1944096"},{"key":"e_1_3_8_10_1","unstructured":"U.S. Food and Drug Administration. [cited 2025 Dec]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=265308"},{"key":"e_1_3_8_11_1","unstructured":"European Medicines Agency. [cited 2025 Dec]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jakavi#authorisation-details"},{"key":"e_1_3_8_12_1","unstructured":"Summary basis of decision - Jakavi - Health Canada. [cited 2025 Dec]. Available from: https:\/\/hpr-rps.hres.ca\/reg-content\/summary-basis-decision-detailOne.php?linkID=SBD00079"},{"key":"e_1_3_8_13_1","unstructured":"Ministry of Food and Drug Safety. [cited 2025 Dec]. Available from: https:\/\/nedrug.mfds.go.kr\/CEAAA21?sort=&sortOrder=&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemEngName=jakavi&entpEngName=&ingrEngName=&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&cancelCode=&etcOtcCode=&makeMaterialGb=&startPermitDate=&endPermitDate"},{"key":"e_1_3_8_14_1","unstructured":"All drug product approval data set. [cited 2025 Dec]. Available from: https:\/\/data.gov.tw\/en\/datasets\/9122?utm"},{"key":"e_1_3_8_15_1","unstructured":"List of approved drugs - April 2004 to June 2025. [cited 2025 Dec]. Available from: https:\/\/www.pmda.go.jp\/files\/000278243.pdf"},{"key":"e_1_3_8_16_1","unstructured":"Anaemia: World Health Organization. 2025 [cited 2025 May]. Available from: https:\/\/www.who.int\/health-topics\/anaemia#tab=tab_1"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05126-4"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234064"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21574"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2279679"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_3_8_29_1","unstructured":"Code of Conduct: European Pharmaceutical Marketing Research Association. 2024 [cited 2025 Sep]. Available from: https:\/\/www.ephmra.org\/sites\/default\/files\/2024-09\/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf1"},{"key":"e_1_3_8_30_1","unstructured":"Health insurance portability and accountability act of 1996. [cited 2025 Sep]. Available from: https:\/\/www.cdc.gov\/phlp\/php\/resources\/health-insurance-portability-and-accountability-act-of-1996-hipaa.html"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382872"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1549023"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206086"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30325"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29753"},{"key":"e_1_3_8_37_1","unstructured":"EuroQol Research Foundation. EQ-5D-5L user guide 2019. [cited 2025 Apr]. Available from: https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-5LUserguide-23-07.pdf"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2692028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2692028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2692028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:42:49Z","timestamp":1786092169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2692028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,7,15]]}},"alternative-id":["10.1080\/14796694.2026.2692028"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2692028","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}